Modality
Multispecific
MOA
SHP2i
Target
CD20
Pathway
Angiogenesis
ADPKDNSCLCHS
Development Pipeline
Preclinical
~Jun 2022
→ ~Sep 2023
Phase 1
~Dec 2023
→ ~Mar 2025
Phase 2
Jun 2025
→ Dec 2027
Phase 2Current
NCT05977181
2,317 pts·NSCLC
2025-06→2027-12·Completed
2,317 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-228mo agoFast Track· ADPKD
2027-12-051.7y awayPh3 Readout· NSCLC
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q4
P2/3
Complet…
Catalysts
Fast Track
2025-07-22 · 8mo ago
ADPKD
Ph3 Readout
2027-12-05 · 1.7y away
NSCLC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05977181 | Phase 2/3 | NSCLC | Completed | 2317 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Doxacagene | Sanofi | Approved | PSMA | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| Daratuximab | BioMarin | Phase 1 | PRMT5 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 |